Provided by Tiger Trade Technology Pte. Ltd.

Cassava Sciences Inc

2.38
0.0000
Volume:- -
Turnover:- -
Market Cap:114.97M
PE:-1.08
High:2.38
Open:2.38
Low:2.38
Close:2.38
52wk High:4.98
52wk Low:1.15
Shares:48.31M
Float Shares:43.48M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1976
EPS(LYR):-1.4620
ROE:-85.44%
ROA:-24.80%
PB:1.41
PE(LYR):-1.63

Loading ...

Cassava Sciences FY 2025 net loss rises 274% to USD 91 million, R&D expenses fall 62% to USD 26.6 million

Reuters
·
Mar 12

Two new option listings and one option delisting on March 11th

TIPRANKS
·
Mar 11

Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker

TIPRANKS
·
Mar 10

Cassava Sciences Changing Name to Filana Therapeutics

MT Newswires Live
·
Mar 10

Cassava Sciences Inc - Changes Name to Filana Therapeutics

THOMSON REUTERS
·
Mar 10

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

GlobeNewswire
·
Mar 10

Cassava Sciences Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
Feb 27

Ensysce Biosciences Executives to Present at USASP Annual Scientific Meeting

Reuters
·
Feb 23

Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased

TIPRANKS
·
Feb 19

BUZZ-Cassava Sciences rises after US DOJ closes probe into company

Reuters
·
Feb 19

Cassava Sciences Says DOJ Closes Investigation

Reuters
·
Feb 19

Cassava Sciences Inc - Indictment Dismissed With Prejudice by DOJ

THOMSON REUTERS
·
Feb 19

Cassava Announces Closure of U.S. Department of Justice Investigation

GlobeNewswire
·
Feb 19

Cassava Sciences And 2 Other Promising Penny Stocks

Simply Wall St.
·
Feb 12

Cassava Sciences announces publication of Phase 3 results for simufilam

TIPRANKS
·
Jan 13

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

GlobeNewswire
·
Jan 13

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

GlobeNewswire
·
Dec 30, 2025

Cassava Sciences Inc: Will Pay $31.25 Mln for Complete Settlement and Release of All Claims

THOMSON REUTERS
·
Dec 23, 2025

Cassava Sciences: to Resolve Litigation Filed in US District Court in Texas

THOMSON REUTERS
·
Dec 23, 2025

Cassava Sciences Settles Securities Class Action for $31.25 Million

Reuters
·
Dec 23, 2025